Cabanillas, Fernando

Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma

Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M., & Kurzrock, R. (1995) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Cited by 164

Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma

Preti, H. A., Cabanillas, F., Talpaz, M., Tucker, S. L., Seymour, J. F., & Kurzrock, R. (1997) · Annals of Internal Medicine

Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Cited by 112

Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid

Estey, E., Thall, P., Mehta, K., Rosenblum, M., Brewer, T. J., Simmons, V, Cabanillas, F., Kurzrock, R., & Lopez-Berestein, G. (1996) · Blood

Retinoids in leukemia and cellular processesPeroxisome Proliferator-Activated Receptors

Cited by 66

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 41